XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (3878)	9/23/1997 8:05:00 PM
From: WL	of 17367

<< Agree it's important news but thought this was only the inital safety study >> My interpretation of paragraph 4 of the 9/22 news release is a little different. Since the new 24 CF patient 'pilot study' is intended to demonstrate safety, this appears to me to correlate somewhat to a Phase II study, IMO. The future placebo-controlled efficacy trials mentioned in the same paragraph look something like a Phase III study, also IMO. Safety studies which have already been done for Nuprex on both the meningo and trauma indications may account for the seemingly low 24 patient count in the new CF pilot study, IMO. It may also be a reflection of the company's confidence in its product, IMO. Someone please correct me if I'm wrong about any of the above.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next